TCF3 single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
TCF3
Disease:
Pre-B-cell acute lymphoblastic leukemia (t(1;19), with PBX1), Childhood leukemia (t(19;19), with TFPT) and Acute leukemia (t(12;19), with ZNF384), endometrial cancer, intestinal cancer, and skin cancer, lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma
Next generation sequencing of gene panel. This gene encodes a member of the E protein (class I) family of helix-loop-helix transcription factors. E proteins activate transcription by binding to regulatory E-box sequences on target genes as heterodimers or homodimers, and are inhibited by heterodimerization with inhibitor of DNA-binding (class IV) helix-loop-helix proteins. E proteins play a critical role in lymphopoiesis, and the encoded protein is required for B and T lymphocyte development.
Specimen Requirements
Collection:
3 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens for RNA gene fusion detection
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81479
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
